Episode Summary
In this episode of Conversations in Lung Cancer Research, A/Prof Mel Moore, along with thoracic oncologists Dr. Malinda Itchins and A/Prof Surein Arulananda, delve into the characteristics, detection, and treatment of EGFR exon 20 insertion mutant non-small cell lung cancer. The podcast discusses recent advances, the efficacy of various treatments including small molecule tyrosine kinase inhibitors and monoclonal antibodies, and the potential future of targeted therapies. Special focus is given to the Phase 3 Papillon study and the drug Amivantamab, highlighting the need for next generation sequencing in clinical settings. Key challenges and questions in the field are also addressed, including the impact of co-mutations and optimal therapy sequencing.
Show Hosts
- A/Prof Melissa Moore, Medical Oncologist at St Vincents Hospital and TOGA Education Chair.
- Dr Malinda Itchins, Medical Oncologist and Clinician Researcher at Chris O’Brien Lifehouse, and Royal North Shore.
- A/Prof Surein Arulananda, Deputy Director of Medical Oncology and Thoracic Oncology trials lead at Monash Health.
Sponsors
This episode is sponsored by Johnson & Johnson.
